Tracking cancer drug outcomes in real indian patients

NCT ID NCT05022342

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study observed how well a specific drug combination (alpelisib plus fulvestrant) worked for Indian patients with a certain type of advanced breast cancer that has a specific genetic mutation (PIK3CA). It also aimed to find out how common this mutation is among Indian patients. The study did not give any treatment; it only collected information from patients whose doctors had already decided to use this drug combination.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Hyderabad, Andhra Pradesh, 500034, India
Novartis Investigative Site

Guwahati, Assam, 781023, India
Novartis Investigative Site

Kochi, Kerala, 682041, India
Novartis Investigative Site

Bhopal, Madhya Pradesh, 462001, India
Novartis Investigative Site

Mumbai, Maharashtra, 400 012, India
Novartis Investigative Site

Mumbai, Maharashtra, 400071, India
Novartis Investigative Site

Nagpur, Maharashtra, 440001, India
Novartis Investigative Site

Nagpur, Maharashtra, 441108, India
Novartis Investigative Site

Pune, Maharashtra, 411004, India
Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, 110060, India
Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, 110092, India
Novartis Investigative Site

Bhubaneshwar, Odisha, 751007, India
Novartis Investigative Site

Bhubaneswar, Odisha, 751003, India
Novartis Investigative Site

Chandigarh, Punjab, 160055, India
Novartis Investigative Site

Ludhiana, Punjab, 141008, India
Novartis Investigative Site

Jaipur, Rajasthan, 302017, India
Novartis Investigative Site

Sherilingampally, Telangana, 500019, India
Novartis Investigative Site

Howrah, West Bengal, 711103, India
Novartis Investigative Site

Kolkata, West Bengal, 700029, India
Novartis Investigative Site

Kolkata, West Bengal, 700054, India
Novartis Investigative Site

Kolkata, West Bengal, 700063, India
Novartis Investigative Site

Ahmedabad, 380054, India
Novartis Investigative Site

Kanpur, 208002, India
Novartis Investigative Site

Kolkata, 700016, India
Novartis Investigative Site

Kolkata, 700026, India
Novartis Investigative Site

Kolkata, 700107, India
Novartis Investigative Site

Puducherry, 605006, India
Novartis Investigative Site

Udaipur, 313011, India

Conditions

Explore the condition pages connected to this study.

BREAST CANCER